Cooperation on the Development of a Malaria Vaccine
The malaria vaccine GMZ2 to be tested in a Phase I clinical trial in Tübingen
GMZ2 (GLURP-MSP3 bivalent vaccine) is a recombinant hybrid protein of GLURP and MSP3 expressed in the L. lactis expression system. GMZ2 is derived from Plasmodium falciparum Glutamate-Rich Protein (GLURP), genetically coupled to P. falciparum Merozoite Surface Protein 3 (MSP3). The aim of the Phase I trial is to evaluate the safety of 3 dosages of GMZ2 (10 µg, 30 µg or 100 µg) adjuvanted with aluminium hydroxide (alum) and given three times over a two month period to healthy adults not previously exposed to the malaria parasite Plasmodium falciparum. The study will take place at the University of Tübingen.
Organizations
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.